Hands-on guidance of a team comprising of more than 120 exempt and non-exempt team members including project coordinators, data analysts, material handlers, production and service managers, technicians, and team members under Food and Drug Administration (FDA) class III pre-market approval (PMA) medical device industry regulations.

• Close supervision of the manufacturing operations, with $30M COGS per year. • Assurance of superior employee safety, product quality, service level, and cost reductions throughout the self-expanding stents factory by implementing operational strategies and process improvements initiatives.• Tactical leadership of 200 exempt and non-exempt employees including managers, supervisors, engineers, technicians, and production associates.• Keen monitoring of multi-site facilities team responsible for overseeing Class A and Class B office spaces and manufacturing facility with International Organization for Standardization (ISO) 8/class 100,000 clean rooms. • Proactive engagement in three new product launches, which involved manufacturing line startup and production administration.• Involvement in decommissioning two manufacturing facilities and moved production to contract manufacturers in Covidien network, while acting as senior manufacturing representative in Northern California.• Implementation of Lean and Six Sigma projects by decreasing product cost by more than $4M.• Accomplishment of the renovation for 30,000-square feet research and development facility worth $3.7M as well as the relocation of 120 employees within the facility in 11 weeks. • Employment of overall problem-solving skills in instituting root cause analysis (RCA) training relating to the deployment of RCA methodology across the plant.• Organization of two projects and minimization of annual material waste by over $500K, as part of the Green Belt program.• Acceptance of the Covidien Bring Home the Gold award by managing the best manufacturing project during the year out of more than 100 hundred project submissions from over 40 manufacturing locations in 2013.

• Orchestration of the daily manufacturing of high-voltage capacitors subassemblies for implantable defibrillators including Class III and active implantable devices. • Achievement of day-to-day production targets encompassing safety, quality, productivity, service level, and cycle time by leading 40 to 80 non-exempt production associates and team leads.• Active participation in procuring medical devices with $30M COGS from contract manufacturers per year.• Identification and execution of productivity improvements which saved $330K labor costs for the management of Lean Conversion Project (LCP) Team.• Rollout of change orders to improve manufacturing processes, while serving as Engineering Change Decision Owner (ECDO).• Key input in saving $296K yearly labor costs by directing cross-functional project team for the establishment of cellular layout.• Obtainment of 50% productivity improvements for two years by implementing Kanban system, Single Minute Exchange of Dies (SMED), 5-S workspace layouts, and Kaizen events.• Establishment of quality accountability policy within the Saint Paul manufacturing site for over 300 product builders.

• Provision of strategic direction to a team of more than 150 non-exempt associates and 9 supervisors in handling the daily distribution for all inbound packages of the St. Paul hub, achieving an average of 20,000 packages hourly.• Optimization of on-time service and productivity by 5% in one year by introducing process improvement program, with 3% net margins.• Driving force behind the achievement of third place ranking for St. Paul Hub out of 30 hubs in the FedEx Ground network in 2008.• Attainment of the Sort Manager of the Year recognition for the fiscal year 2008 at Saint Paul hub.

• Thorough evaluation and organization debt products, in partnership with the Client Management Team.• Close coordination with senior credit products personnel in underwriting credit facilities with $100M outstanding total loans.• Administration of loan portfolio amounting to more than $500M. • Determination of risk factors by evaluating financial statements and business models.• Supervision of junior credit products personnel responsible for managing portfolio to guarantee effective risk rating classification and financial statement analysis.• Obtainment of $3M total loan and loan equivalent exposure and $5M Automated Clearing House ACH approval authority.